Pancreatic Cancer Research

ResearcherTokyo Women's Medical UniversityActive in the last 2 years

Yukiko Takayama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4440-0298; OpenAlex author ID A5112096329, A5129848410. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 9

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. Co-author DOI 10.1016/j.pan.2025.02.005↗
  5. Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications. Co-author DOI 10.3390/cancers17111765↗
  6. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  7. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  8. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3611-y↗
  9. [An algorithm in the investigation and diagnosis of pancreatic cancer]. Co-author PMID 25856996↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Kobayashi · 3 shared papers, 2023–2026 · strength 0.52
  2. Masafumi Ikeda · 3 shared papers, 2023–2026 · strength 0.52
  3. Masato Ozaka · 3 shared papers, 2023–2026 · strength 0.52
  4. Junji Furuse · 3 shared papers, 2023–2026 · strength 0.52
  5. Nao Fujimori · 3 shared papers, 2023–2026 · strength 0.52
  6. Makoto Ueno · 3 shared papers, 2023–2026 · strength 0.52
  7. Nao Otsuka · 2 shared papers, 2018–2025 · strength 0.43
  8. Yusuke Sano · 2 shared papers, 2025–2026 · strength 0.40
  9. Masashi Kanai · 2 shared papers, 2025–2026 · strength 0.40
  10. Yousuke Nakai · 1 shared paper, 2025 · strength 0.33
  11. Junki Mizusawa · 2 shared papers, 2023–2026 · strength 0.33
  12. Yoshito Komatsu · 2 shared papers, 2023–2026 · strength 0.33
  13. Ken Kamata · 2 shared papers, 2023–2026 · strength 0.33
  14. Takuji Okusaka · 2 shared papers, 2023–2026 · strength 0.33
  15. Naoki Sasahira · 2 shared papers, 2023–2026 · strength 0.33
  16. Akiko Todaka · 2 shared papers, 2023–2025 · strength 0.32
  17. Akihiro Ohba · 2 shared papers, 2023–2025 · strength 0.32
  18. Akio Katanuma · 2 shared papers, 2023–2025 · strength 0.32
  19. Atsushi Kanno · 1 shared paper, 2026 · strength 0.22
  20. Mamoru Takenaka · 1 shared paper, 2026 · strength 0.22
  21. Reiko Ashida · 1 shared paper, 2026 · strength 0.22
  22. Yasutaka Ishii · 1 shared paper, 2026 · strength 0.22
  23. Noboru Ideno · 1 shared paper, 2026 · strength 0.22
  24. Takao Ohtsuka · 1 shared paper, 2026 · strength 0.22
  25. Shujiro Yazumi · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.